Characterisation of 2-HP-β-cyclodextrin-PLGA nanoparticle complexes for potential use as ocular drug delivery vehicles
Source abstract
Abstract
Aim: 2-HP-β-cyclodextrin-PLGA nanoparticle complexes were prepared to enhance the aqueous humour delivery of Triamcinolone acetonide.Materials & methods: Drug-loaded 2-HP-β-CD/PLGA nanoparticle complexes prepared by adapting a quasi-emulsion solvent evaporation technique. In vitro drug release, in vitro transcorneal permeation study, histopathological study and in vivo transcorneal penetration of PLGA nanoparticles and 2-HP-β-CD/PLGA nanoparticle complexes were evaluated. Results: Particle size distributions of 2-HP-β-CD/PLGA nanoparticle complexes were 149.4 ± 3.7 nm and presented stable system. Corneal penetration studies revealed steady sustained drug release (First-order); 2-HP-β-CD/PLGA nanoparticle complexes increased ocular bioavailability by increasing dispersion in the tear film and improving drug release. Conclusion: 2-HP-β-CD/PLGA nanoparticle complex formulation is a promising alternative to conventional eye drops.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems, Guangdong Pharmaceutical University
Guangdong Provincial Engineering Center of Topical Precise Drug Delivery Systems, Guangdong Pharmaceutical University
R&D Team for Formulation Innovation, Guangdong Pharmaceutical University
Department of Hospital Pharmacy, Ningbo 7 Hospital
Funding
R&D Team for Formulation Innovation · Guangdong Pharmaceutical University · Guangdong “Climbing” Programme
References (46)
Show source-provided references
1. 10.2217/nnm-2017-031810.2217/nnm-2017-0318 ↗
2. 10.2147/IJN.S12619910.2147/IJN.S126199 ↗
3. 10.1016/j.clae.2017.06.00310.1016/j.clae.2017.06.003 ↗
4. 10.4103/2231-4040.14302210.4103/2231-4040.143022 ↗
5. 10.4103/tjo.tjo_75_1710.4103/tjo.tjo_75_17 ↗
6. 10.3109/10837450.2015.112592210.3109/10837450.2015.1125922 ↗
7. 10.1016/j.jconrel.2018.06.03110.1016/j.jconrel.2018.06.031 ↗
8. 10.1007/s11095-017-2319-810.1007/s11095-017-2319-8 ↗
9. 10.1016/j.biopha.2017.07.11010.1016/j.biopha.2017.07.110 ↗
10. 10.1016/j.nano.2009.10.00410.1016/j.nano.2009.10.004 ↗
11. 10.1002/jbm.a.3544610.1002/jbm.a.35446 ↗
12. 10.1208/s12249-017-0710-810.1208/s12249-017-0710-8 ↗
13. 10.1093/protein/gzg13710.1093/protein/gzg137 ↗
14. 10.2147/IJN.S2848110.2147/IJN.S28481 ↗
15. 10.2174/138161282266616121611320710.2174/1381612822666161216113207 ↗
16. 10.3109/10837450.2012.70529810.3109/10837450.2012.705298 ↗
17. Huang X. Preparation and preliminary study of targeting of cyclodextrin coated PLGA nanoparticles [master’s thesis]. Guangzhou: Guangdong Pharmaceutical University; 2018.
18. 10.1016/0032-3861(81)90230-510.1016/0032-3861(81)90230-5 ↗
19. 10.1002/pen.76023120410.1002/pen.760231204 ↗
20. 10.1007/s10973-011-1299-x10.1007/s10973-011-1299-x ↗
21. 10.1007/s10792-018-0955-610.1007/s10792-018-0955-6 ↗
22. Macri A, Marini V, Sangalli G, et al. An artificial aqueous humor as a standard matrix to assess drug concentration in the anterior chamber by high performance liquid chromatography methods. Clin Lab. 2015;61(1–2):47–52.
23. 10.1080/0271368059093409410.1080/02713680590934094 ↗
24. Malhotra M, Majumdar DK. In vitro transcorneal permeation of ketorolac tromethamine from buffered and unbuffered aqueous ocular drops. Indian J Exp Biol. 1997;35(9):941–947.
25. 10.1016/S0039-6257(01)00211-910.1016/S0039-6257(01)00211-9 ↗
26. 10.1093/bmb/ldv00210.1093/bmb/ldv002 ↗
27. 10.1002/9780470571224.pse19610.1002/9780470571224.pse196 ↗
28. L Nnroth P, Jansson PA, Smith U. A microdialysis method allowing characterization of intercellular water space in humans. Am J Phys. 1987;253(1):228–231.
29. 10.1016/j.tca.2005.09.01110.1016/j.tca.2005.09.011 ↗
30. 10.1615/CritRevTherDrugCarrierSyst.v21.i3.1010.1615/CritRevTherDrugCarrierSyst.v21.i3.10 ↗
31. 10.1208/pt06023210.1208/pt060232 ↗
32. 10.1208/s12248-008-9024-910.1208/s12248-008-9024-9 ↗
33. 10.1016/j.ejpb.2015.04.03210.1016/j.ejpb.2015.04.032 ↗
34. Bozkir A, Denli ZF, Basaran B. Effect of hydroxypropyl-beta-cyclodextrin on the solubility, stability and in-vitro release of ciprofloxacin for ocular drug delivery. Acta Pol Pharm. 2012;69(4):719–724.
35. 10.1016/j.ijpharm.2017.04.01010.1016/j.ijpharm.2017.04.010 ↗
36. 10.1016/S0169-409X(00)00112-510.1016/S0169-409X(00)00112-5 ↗
37. 10.5713/ajas.14.076110.5713/ajas.14.0761 ↗
38. 10.2174/18722105090215081915184110.2174/187221050902150819151841 ↗
39. 10.1016/S0927-7765(99)00105-810.1016/S0927-7765(99)00105-8 ↗
40. 10.1016/j.ejps.2011.06.00710.1016/j.ejps.2011.06.007 ↗
41. 10.1016/j.ejps.2012.04.01310.1016/j.ejps.2012.04.013 ↗
42. 10.1016/j.jconrel.2005.11.01410.1016/j.jconrel.2005.11.014 ↗
43. 10.1016/S0927-7765(00)00148-X10.1016/S0927-7765(00)00148-X ↗
44. 10.1016/S0378-5173(98)00369-X10.1016/S0378-5173(98)00369-X ↗
45. Bibby DC, Davies NM, Tucker IG. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. The Netherlands: Elsevier B.V; 2000. p. 1–11.
46. Gã Rsoy A, Tã Rkoä Lu M, Senyã Cel B, et al. Evaluation of tableted microspheres of dipyridamole. Drug Dev Commun. 1995;21(4):503–507.